Cartesian Therapeutics
In November 2023, Selecta Biosciences Inc. (NASDAQ: SELB) merged with Cartesian Therapeutics to create a publicly traded company pioneering RNA cell therapy to treat autoimmune disease. The combined company will focus on advancing Cartesian’s wholly owned pipeline, including Descartes-08, Cartesian’s clinical-stage lead product candidate being evaluated in patients with myasthenia gravis and other autoimmune diseases. Cartesian Therapeutics is a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases. Leveraging its proprietary RNA Armory® platform, Cartesian’s internally manufactured portfolio is purposefully designed to be administered conveniently in an outpatient setting without preconditioning chemotherapy. The Company’s portfolio includes its Phase 2 lead asset, Descartes-08, an autologous anti-BCMA mRNA CAR-T.
Company details
Find locations served, office locations
- Business Type:
- Technology
- Industry Type:
- Clinical Services
- Market Focus:
- Nationally (across the country)
- Year Founded:
- 2008
Welcome
OUR MISSION
UNLOCKING THE POWER OF BIOLOGICS
Developing selective tolerogenic therapies and restoring self-tolerance in autoimmune diseases.
Our Purpose
Selecta Biosciences is a clinical-stage biotechnology company with an unrelenting commitment to overcoming immunogenicity with our pioneering ImmTOR™ immune tolerance platform.
About Us
Diversity & Inclusion
Selecta Biosciences is led by a group of veteran scientists and entrepreneurs that have built a creative, diverse and engaging work environment that is embodied by the entirety of the team.
These professionals rely on diversity collaboration, and an inclusive work environment to advance Selecta’s pipeline.
CORPORATE STRATEGY
Selecta possesses the key tools necessary to successfully achieve its mission of overcoming immunogenicity through its pioneering ImmTOR platform to transform the lives of patients and their families. With a strong leadership team, Selecta has formed strategic partnerships with leading biopharmaceutical and gene therapy companies. Selecta intends to both advance its wholly owned, proprietary pipeline and work with partners, with the goal of addressing immunogenicity to create life-changing therapies for patients and their families.